Heavy cannabis use and psychotic-like symptoms: what a 2026 study of 150 adults found
In 150 clinic adults, daily cannabis went with more mild paranoia-like and depressive symptoms. What the Italy study measured, limits, and what trainers should log.
revns editorial · Published November 19, 2026 · 8 min read

Ricci et al. compared 150 Italian clinic adults (heavy, occasional or no cannabis). Heavy users scored higher on mild psychotic-like and depressive symptoms; the design cannot prove cause.
Heavy cannabis use went with higher scores for mild paranoia-like thoughts and depressive symptoms in 150 adults already in psychiatric care, but the study cannot prove cannabis caused those symptoms. Researchers led by Valerio Ricci compared daily heavy users, monthly occasional users and non-users in clinics across Italy, publishing in the Journal of Psychiatric Research (DOI 10.1016/j.jpsychires.2026.06.055). Heavy users averaged about 2.8 grams per day; occasional users averaged about 3.2 grams per month. If you train and wonder whether cannabis and mental health habits belong in your log, the practical point is frequency, age you started, sleep and functioning — not treating the drug as medicine.
TL;DR
| Topic | What Ricci et al. report (n = 150, ages 18–40, Italy) |
|---|---|
| Groups | 43 heavy (≥5 days/week), 47 occasional (1–4 times/month), 60 non-users |
| Heavy use amount | ~2.8 g/day average (self-report + urine screen) |
| Main finding | Heavy users higher on positive psychotic-like symptoms and depressive symptoms vs other groups |
| Occasional users | Higher than abstainers, lower than heavy users on those scales |
| Negative symptoms | No significant difference across groups (motivation, flat mood scales) |
| Age started | Before ~16.4 years linked to higher symptom scores vs later starters |
| Functioning | Heavy users scored worse on clinician global functioning ratings |
| Tobacco | Heavy cannabis plus daily tobacco tied to higher positive symptom scores |
| Design limit | Cross-sectional — one snapshot; causation and self-medication both possible |
| Training takeaway | Log mood, sleep and sessions; cannabis is not a mental-health treatment |

What did the 2026 cannabis study measure?
Ricci and colleagues recruited 150 adults aged 18 to 40 from psychiatric outpatient clinics in Italy. Participants were in care for non-psychotic issues such as anxiety or mood problems. The team excluded anyone with a current or past psychotic disorder and anyone with an immediate relative with psychotic illness, so the sample sits between general population volunteers and schizophrenia research.
Participants split into three groups by self-reported cannabis habits, checked against urine toxicology:
| Group | Size | Use pattern (study definition) |
|---|---|---|
| Heavy | 43 | Cannabis on 5 or more days per week |
| Occasional | 47 | 1 to 4 times per month |
| Non-users | 60 | No cannabis history |
Consumption volume diverged sharply. Heavy users reported about 2.8 grams per day on average. Occasional users reported about 3.2 grams across an entire month. Heavy users mostly smoked; occasional users more often used vaporisers, the authors note.
Symptoms came from the Community Assessment of Psychic Experiences (CAPE) questionnaire, a standard tool for mild psychotic-like experiences. Participants rated how often they had:
- Positive-type items — unusual perceptions or beliefs (for example feeling detached from your body or that others read your mind).
- Depressive items — low mood and related thoughts.
- Negative-type items — reduced motivation or emotional expression.
Clinicians also rated global functioning and clinical impression with standard scales (GAF and CGI in the paper). Those scores describe how well someone manages work, relationships and daily tasks, which matters if you are trying to hold a training block together.
How does cannabis affect mental health in this sample?
Heavy users reported more positive psychotic-like symptoms and more depressive symptoms than occasional users and than non-users. Occasional users generally scored between the two other groups. Symptom severity rose with use frequency in the analysis the authors describe.
Negative symptoms — such as amotivation or flattened affect on the CAPE negative subscale — did not differ significantly across the three groups. The researchers suggest questionnaires may miss subtle motivation problems, but the headline is that the clearest gaps were on mild positive and depressive items, not on every symptom category.
Age at first use mattered. Participants who began cannabis before about 16.4 years had higher symptom scores than those who started later. Longer total duration of use followed a similar pattern. Adolescence is when the brain's endocannabinoid system is still developing; introducing high THC exposure in that window is biologically plausible as a risk factor, but this study does not measure brain imaging or prove that mechanism in these individuals.
Daily functioning was lower in the heavy-use group on clinician ratings. Occasional users did not show the same drop in those functioning scores. For someone who trains, that pattern fits what coaches see informally: when mood and perception feel off, consistency, not peak power, is often what slips first.
The authors also report a cannabis–tobacco interaction. Among heavy cannabis users, those who smoked tobacco daily had higher positive symptom scores than heavy users who used tobacco less often. Both nicotine and THC affect reward pathways; combined use may amplify subjective effects. Alcohol, stimulants and other drugs were included in models but did not independently predict symptom severity in the way frequency did.

Can cannabis cause psychosis or only mild symptoms?
Searchers often ask whether cannabis can cause psychosis. This paper is not a psychosis-incidence study. Everyone with a psychotic disorder was excluded. What increased were subclinical scores — phenomena that resemble psychosis at low intensity.
Epidemiological work cited in the paper suggests roughly 7 to 13 percent of the general population report such experiences at some point, often without ever meeting criteria for schizophrenia. That distinction matters:
- Psychotic-like experiences on a survey are not a diagnosis.
- Hallucinations, fixed delusions or severe disorganisation that persist or escalate need urgent psychiatric assessment, regardless of cannabis use.
The study design is cross-sectional: one visit, no follow-up. The team cannot tell whether heavy use preceded symptoms or whether people with emerging perceptual oddities used more cannabis to cope — the self-medication hypothesis the authors list openly. Both directions are compatible with the numbers.
The investigators also relied on self-report for use history and did not assay THC potency of products. High-potency concentrates may carry different risk than low-THC herbal cannabis; that gap is important for policy and for individuals, but this dataset does not grade products.
Is cannabis bad for mental health if you are otherwise healthy?
This sample is not a cohort of unselected gym members. Every participant was in psychiatric care, which means higher baseline vulnerability than the general population. You should not read the group means as your personal forecast.
Still, the paper offers caution for people who train:
- Frequency correlated with symptom burden even within this already-selected group.
- Early and prolonged use tracked with higher scores — relevant for coaches working with younger athletes.
- Functioning scores dipped in heavy users, which can show up as missed sessions, social withdrawal from team training, or blunt mood before deload decisions.
Cannabis is not listed in major activity guidelines as a recovery aid. It is also not a substitute for sleep hygiene, stress load management, walking, or clinical care when mood disorders are present. revns does not prescribe, supply or endorse cannabis use.
What should you do this week if you use cannabis?
This is habit tracking, not a quit plan and not medical advice.
For two weeks, on paper or in revns, log on the same days:
| Field | Why |
|---|---|
| Cannabis use (yes/no, time, method) | Matches the paper's frequency focus |
| Sleep hours and wake time | THC often disrupts late-night sleep architecture |
| Mood or tension (1–5) | Mirrors CAPE-style self-monitoring |
| Training completed (type, RPE) | Separates drug effects from overreach |
| Alcohol and caffeine | Other drugs in the study's models |
Use mood and energy tracking next to sessions. If you connect an AI assistant through MCP, ask pattern questions ("Did mood dip on days after late THC use?") — not for a diagnosis.
Do not add high-intensity intervals to "burn off" anxiety the morning after heavy use. If rest days are missing because recovery feels slow, fix sleep and load before you stack more stress.
Compare with other mental-health habits that have separate evidence: daylight and mood, caffeine and alcohol timing, and deload timing.
When should you see a professional?
Get clinical help — not just a training tweak — if any of the following apply:
- Low mood, panic or loss of interest most days for two weeks or more.
- Unusual perceptions that scare you, that others notice, or that stop you working or training safely.
- You need cannabis (or alcohol) to sleep, train or face the day most days.
- Chest pain, fainting or racing heart with anxiety or with exercise.
- Thoughts of self-harm or that others would be better off without you.
Emergency care is appropriate for sudden severe confusion, commanding voices telling you to act, or behaviour that puts you or others at immediate risk.
Crisis lines (free, 24/7 where listed):
- United States: call or text 988 (Suicide & Crisis Lifeline).
- United Kingdom and Ireland: Samaritans 116 123 (no area code needed).
- Elsewhere: search your national crisis line or ask a GP the same day.
Cannabis withdrawal, cannabis use disorder and psychotic illnesses all need qualified clinicians. An app or AI coach does not treat any of them.
What does this study not prove?
Keep these limits in the same sentence as any headline:
- No causation — one time point only.
- Selected sample — psychiatric clinic patients, not random athletes.
- No potency data — THC and cannabinoid profiles unknown.
- Questionnaires — CAPE items do not equal clinical interview.
- Other meds — some participants used psychiatric prescriptions that could influence reporting.
- Not generalisable geography — Italian clinic population; laws and products differ elsewhere.
Future work the authors want includes longitudinal follow-up and chemical analysis of strains. Until then, treat heavy use as a risk marker to respect, not as a reason to panic over one odd thought after a sleepless week.
Related
- Anxiety, caffeine, alcohol and sleep: a tracking guide
- How to track mood and energy next to training
- Men's mental health: why it goes unspoken and small habits that help
- Stress, burnout and when to deload
- Walking and mental health: how many steps help mood
- Fruits and vegetables for depression risk: 2026 meta-analysis
- AI fitness coach
This is general training guidance, not medical advice.
Sources
- Ricci V et al. Cannabis use patterns and psychotic-like experiences: a cross-sectional study of heavy users, occasional users, and non-users. J Psychiatr Res. 2026. doi:10.1016/j.jpsychires.2026.06.055
- Ricci V et al. Cannabis use and psychotic-like experiences: A systematic review of biological vulnerability, potency effects, and clinical trajectories. Psychiatry Res. 2025;348:116496
- National Health Service. Generalised anxiety disorder in adults — self-help. Updated periodically.
Terms in this post
revns publishes training and nutrition guidance, not medical advice. See a clinician for symptoms, injury or a medical condition. Accurate as of November 19, 2026.

